Citation Impact
Citing Papers
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Biocatalytic Asymmetric Synthesis of Chiral Amines from Ketones Applied to Sitagliptin Manufacture
2010 Science
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
2013
Obesity Stigma: Important Considerations for Public Health
2010 Standout
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial
2016
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Pharmacotherapy of type 2 diabetes: An update
2017
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
2016
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2018 Standout
Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes
2014
Wearable biosensors for healthcare monitoring
2019 Standout
Cytochrome P450: taming a wild type enzyme
2011 StandoutNobel
Colorectal cancer screening among obese versus non-obese patients in primary care practices
2006
Computational Enzyme Design
2013 StandoutNobel
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
2012
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
2021
Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus
2008
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
2014
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
2013
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
The road to fully programmable protein catalysis
2022 StandoutNatureNobel
Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals
2019
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
2012
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
2016
Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program
2011
Susceptibility genes in Graves’ ophthalmopathy: searching for a needle in a haystack?
2007
Expanding the Enzyme Universe: Accessing Non‐Natural Reactions by Mechanism‐Guided Directed Evolution
2015 StandoutNobel
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
2017
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
2012
The gut as a sensory organ
2013
Cardiovascular effects of gliptins
2013
Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors
2010
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Diabetes in Asia
2009 Standout
High-performance medicine: the convergence of human and artificial intelligence
2018 Standout
Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor
2015
Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis
2017
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
Graves' Ophthalmopathy
2010 Standout
Incretins as a novel therapeutic strategy in patients with diabetes and heart failure
2012
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
2012
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
2013 Standout
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
2012
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
2015 Standout
Type 2 diabetes
2017 Standout
Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways
2017 StandoutNobel
The potential for renoprotection with incretin-based drugs
2014
Cytokine gene polymorphism in human disease: on-line databases
1999
Highly Stereoselective Biocatalytic Synthesis of Key Cyclopropane Intermediate to Ticagrelor
2016 StandoutNobel
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
2014
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
2010
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
2013
Enzymatic functionalization of carbon–hydrogen bonds
2010 StandoutNobel
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Activation of the Luteinizing Hormone Receptor Following Substitution of Ser-277 with Selective Hydrophobic Residues in the Ectodomain Hinge Region
2000 StandoutNobel
The Discovery and Development of Liraglutide and Semaglutide
2019
Glucotypes reveal new patterns of glucose dysregulation
2018
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
G protein-coupled receptors as targets for anti-diabetic therapeutics
2016
Measuring glucose exposure and variability using continuous glucose monitoring in normal and abnormal glucose metabolism in pregnancy
2012
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial
2019
Sitagliptin Manufacture: A Compelling Tale of Green Chemistry, Process Intensification, and Industrial Asymmetric Catalysis
2011
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
2017
Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
2010
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
2013 Standout
Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome
2011
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
2017
Interleukin-1 polymorphisms associated with increased risk of gastric cancer
2000 StandoutNature
Engineering the third wave of biocatalysis
2012 StandoutNature
New Insulins and New Aspects in Insulin Delivery
2015
Immunoregulatory and Susceptibility Genes in Thyroid and Polyglandular Autoimmunity
2005
Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities
2016
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Management of Graves’ Ophthalmopathy: Reality and Perspectives*
2000
Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes
2012
Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes
2014
Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials
2015
Harnessing the ambiphilicity of silyl nitronates in a catalytic asymmetric approach to aliphatic β3-amino acids
2021 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in J apanese patients (LEAN ‐J )
2014
The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies*
1998
Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin‐treated type 1 and type 2 diabetes: the global HAT study
2016
Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis
2016
Tirzepatide Once Weekly for the Treatment of Obesity
2022 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments
2015
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1)
2013
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
Cardiovascular Biology of the Incretin System
2012
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
2017
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
2016 Standout
Real‐world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review
2013
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Diabetes and Cancer
2010 Standout
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis
2016
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association
2015
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence
2015
The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis
2018 Standout
First Clinical Experience with Retrospective Flash Glucose Monitoring (FGM) Analysis in South Africa
2016
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
2016
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
2013
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
2014
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial ( BEGIN : ADD TO GLP ‐1 S tudy)
2016
Mechanisms of Diabetic Complications
2013 Standout
Current Perspective on the Pathogenesis of Graves’ Disease and Ophthalmopathy
2003
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Inflammatory responses and inflammation-associated diseases in organs
2017 Standout
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
2011
Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control
2015
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
2013 Standout
Clinical Update: Cardiovascular Disease in Diabetes Mellitus
2016
Review of basal‐plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus
2017
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
2012 Standout
GLP-1 receptor agonists today
2011
Depression Predicts All-Cause Mortality
2012
Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
2015
Industrial biotechnology—the future of green chemistry?
2011
Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus
2014
Management of Graves' Ophthalmopathy: Reality and Perspectives
2000
Works of Robert Cuddihy being referenced
Continuous Glucose Monitoring Reveals Different Glycemic Responses of Moderate- vs High-Carbohydrate Lunch Meals in People with Type 2 Diabetes
2010
Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
2010
Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin
2010
Considerations for Diabetes
2011
Ambulatory glucose profile (AGP): development of a common, web-based application to record and report continuous glucose monitoring data
2009
The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study
2010
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
2011
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
2010
Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
2009
A Polymorphism in the Extracellular Domain of the Thyrotropin Receptor Is Highly Associated with Autoimmune Thyroid Disease in Females
1995
Women with Diabetes Have Poorer Control of Blood Pressure Than Men
2005
Exenatide Once-Weekly Clinical Development: Safety and Efficacy Across a Range of Background Therapies
2011
Characterizing Glucose Exposure for Individuals with Normal Glucose Tolerance Using Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis
2008
Lack of an association between alleles of interleukin-1 alpha and interleukin-1 receptor antagonist genes and Graves' disease in a North American Caucasian population
1996
A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes
2011
Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
2009
Screening Mammogram Utilization in Women With Diabetes
2001
International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
2011
Type 2 Diabetes Care and Insulin Intensification
2010
Effect of Intensive Glycemic Lowering on Health-Related Quality of Life in Type 2 Diabetes
2011
Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
2011
Lack of an association between alleles of interleukin-1 alpha and interleukin-1 receptor antagonist genes and Graves' disease in a North American Caucasian population.
1996